NCT01754935 - A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

February 28, 2014

Conditions

Rheumatoid Arthritis

Interventions

DRUG

VX-509

50 mg oral tablet

DRUG

VX-509 matching placebo

0 mg oral tablet

Trial Locations (30)

Unknown

Vertex Investigational Site, Stanford

Vertex Investigational Site, Upland

Vertex Investigational Site, Fort Lauderdale

Vertex Investigational Site, Venice

Vertex Investigational Site, West Palm Beach

Vertex Investigational Site, Canton

Vertex Investigational Site, Decatur

Vertex Investigational Site, Kansas City

Vertex Investigational Site, Elizabethtown

Vertex Investigational Site, Frederick

Vertex Investigational Site, Lincoln

Vertex Investigational Site, Rochester

Vertex Investigational Site, Greenboro

Vertex Investigational Site, Duncansville

Vertex Investigational Site, Charleston

Vertex Investigational Site, Memphis

Vertex Investigational Site, Katy

Vertex Investigational Site, San Antonio

Vertex Investigational Site, Webster

Vertex Investigational Site, Seattle

Vertex Investigational Site, Spokane

Vertex Investigational Site, Hillerød

Vertex Investigational Site, Hjørring

Vertex Investigational Site, Tallinn

Vertex Investigational Site, Vilnius

Vertex Investigational Site, Heerlen

Vertex Investigational Site, Utrecht

Vertex Investigational Site, Johannesburg

Vertex Investigational Site, Pretoria

Vertex Investigational Site, Stellenbosch

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY